Company
Cerenovus
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
9
As lead sponsor, any status
Adverse event reports
84
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Cerenovus, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Cerenovus.
Latest FDA decisions
The 8 newest of 11 since 2015.
K262419 · Decided Aug 14, 2026 · 30 days after receipt
Device type: Device, Neurovascular Embolization (HCG) · Neurology & Neurosurgery
K262398 · Decided Aug 13, 2026 · 30 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
- TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural SetPMA supplement
P990040-S034 · Decided Dec 16, 2025 · 316 days after receipt · Panel Track
Device type: Neurovascular Liquid Embolic Agent (SGU) · Neurology & Neurosurgery
8 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- MMA Embolization for Refractory Chronic MigraineActive, not recruiting
NCT06735833 · 31 participants · Start Apr 23, 2025 · Primary completion Dec 25, 2026
Device: Middle Meningeal Artery embolization · For: Migraine Disorders
Sites: Walnut Creek, California; Hartford, Connecticut; Buffalo, New York · 8 sites in all
- Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCAPivotal-lookingCompleted
NCT04816591 · 376 participants · Start May 27, 2021 · Primary completion Aug 15, 2024
Device: Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System; Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System · For: Chronic Subdural Hematoma
Sites: Birmingham, Alabama; Tucson, Arizona; Walnut Creek, California · 33 sites in all
NCT03642639 · 723 participants · Start Aug 23, 2018 · Primary completion Jun 12, 2025
Device: MICRUSFRAME and GALAXY coils · For: Aneurysms
Sites: Tucson, Arizona; Carmichael, California; Orange, California · 51 sites in all
6 more trials with a free account
Reports received
84
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
68
81% of reports
Injury reports
15
18% of reports
Death reports
1
1.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 3 | 2 | 0 | 0 |
| Jan 24 | 2 | 2 | 1 | 0 |
| Feb 24 | 1 | 1 | 0 | 0 |
| Mar 24 | 9 | 2 | 0 | 0 |
| Apr 24 | 3 | 1 | 0 | 0 |
| May 24 | 1 | 5 | 0 | 0 |
| Jun 24 | 1 | 2 | 0 | 0 |
| Jul 24 | 6 | 4 | 0 | 0 |
| Aug 24 | 3 | 1 | 0 | 0 |
| Sep 24 | 2 | 1 | 0 | 0 |
| Oct 24 | 2 | 4 | 0 | 0 |
| Nov 24 | 4 | 3 | 0 | 0 |
| Dec 24 | 7 | 3 | 0 | 0 |
| Jan 25 | 6 | 1 | 0 | 0 |
| Feb 25 | 4 | 0 | 0 | 0 |
| Mar 25 | 1 | 2 | 0 | 0 |
| Apr 25 | 2 | 2 | 1 | 0 |
| May 25 | 3 | 5 | 0 | 0 |
| Jun 25 | 4 | 0 | 1 | 0 |
| Jul 25 | 5 | 1 | 0 | 0 |
| Aug 25 | 7 | 0 | 0 | 0 |
| Sep 25 | 6 | 1 | 0 | 0 |
| Oct 25 | 2 | 2 | 0 | 0 |
| Nov 25 | 7 | 0 | 0 | 0 |
| Dec 25 | 4 | 1 | 0 | 0 |
| Jan 26 | 3 | 2 | 0 | 0 |
| Feb 26 | 7 | 1 | 1 | 0 |
| Mar 26 | 10 | 2 | 0 | 0 |
| Apr 26 | 7 | 1 | 0 | 0 |
| May 26 | 6 | 2 | 0 | 0 |
| Jun 26 | 9 | 3 | 0 | 0 |
| Jul 26 | 8 | 0 | 0 | 0 |
| Aug 26 | 1 | 1 | 0 | 0 |
| Sep 26 | 4 | 1 | 0 | 0 |
| Oct 26 | 2 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
2 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- ENVOY13
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0434-2026 · Started Oct 2, 2025 · Posted by FDA Nov 13, 2025
Reason given: Detachable coils system may fail to detach, which could result in hemorrhagic and ischemic stroke, procedural delays, or the need for additional surgical intervention.
Cause as FDA categorized it: Under Investigation by firm · Device type: Device, Neurovascular Embolization (HCG)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.